Scarica l'app Stockscreener
273.92
2.42%
-7.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Transthyretin Amyloidosis Treatment Market Detailed In New - openPR
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India
Alnylam Pharmaceuticals CMO Pushkal Garg sells $2.86 million in stock By Investing.com - Investing.com UK
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com India
FDA approves new drug to treat protein buildup in the heart - UPI News
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga
FDA OKs Amvuttra To Treat Heart Conditions - The Daily Courier
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis - Value the Markets
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - Yahoo Finance
RBC Capital holds $330 target on Alnylam stock post-Amvuttra approval - Investing.com UK
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280 - Marketscreener.com
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
JPMorgan raises Alnylam stock rating, lifts target to $328 - Investing.com
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision - Simply Wall St
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? - Benzinga
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer - MSN
Alnylam price target raised to $338 from $300 at Scotiabank - Yahoo Finance
Alnylam Pharmaceuticals’ SWOT analysis: RNAi leader’s stock poised for growth in ATTR-CM market - Investing.com
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Alnylam Stock Jumps After the FDA Approves Its Heart Drug - The Wall Street Journal
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (NASDAQ:ALNY) - Seeking Alpha
U.S. Markets Moved Upward Friday; Alnylam Pharmaceuticals Climbed Highest - Barron's
Alnylam: US Approval of Amvuttra in ATTR-CM Significantly Expands Addressable Patient Population - Morningstar
Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease - Endpoints News
Buy, Sell, Or Hold Alnylam Stock At $280? - Forbes
Check Out What Whales Are Doing With ALNY - Benzinga
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval - TipRanks
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - Yahoo Finance
Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects - MSN
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Expanded Heart Drug Approval Sets Up Pfizer Challenge - MSN
Alnylam's Amvuttra Gains Expanded US Approval for Heart ConditionNews and Statistics - IndexBox, Inc.
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating - Marketscreener.com
Alnylam Pharmaceuticals Shares Rise After Receipt of US FDA Approval for ATTR-CM Drug - Marketscreener.com
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga
Sector Update: Health Care -March 21, 2025 at 09:20 am EDT - Marketscreener.com
Sector Update: Health Care - TradingView
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating - Marketscreener.com
Alnylam scores a first with FDA nod for Amvuttra in ATTR-CM - The Pharma Letter
Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com
Alnylam stock rises after FDA nod for AMVUTTRA By Investing.com - Investing.com Canada
Alnylam joins three-way contest in ATTR cardiomyopathy - pharmaphorum
Alnylam’s SWOT analysis: biotechnology stock poised for growth amid ATTR-CM market expansion - Investing.com
Alnylam Pharmaceuticals Recieives US FDA Approval for ATTR-CM Drug -March 21, 2025 at 03:59 am EDT - Marketscreener.com
Alnylam drug gets long-awaited FDA approval in deadly heart disease - BioPharma Dive
FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy - CGTLive™
Alnylam nabs key additional indication for Amvuttra - MSN
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - BioSpace
US FDA expands approval for Alnylam's drug to treat rare heart disease - Reuters
Alnylam wins FDA approval for rare heart disease drug - The Business Journals
FDA approves first dual-action treatment for ATTR amyloidosis - Investing.com India
Amvuttra’s label expansion lifts Alnylam toward five-year goals - BioCentury
3.14%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):